About
Priothera Limited develops innovative immune modulator therapies, including the investigational drug mocravimod, to improve outcomes in patients with hematological malignancies by enhancing the efficacy and safety of hematopoietic cell transplantation and CAR T cell therapies.
Explore Priothera Limited's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.